RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Semax is a synthetic seven-amino-acid peptide studied in neuroscience. Its literature spans molecular measurements in rats, exploratory imaging in healthy people and clinical reports in stroke rehabilitation. These findings differ in what they can establish. This article reviews three original publications while separating changes in biological markers from demonstrated functional outcomes and avoiding claims of universal cognitive enhancement. [1–3]
BDNF AND TRKB FINDINGS IN RATS
Dolotov and colleagues examined Semax in rats in 2006. They reported changes in hippocampal BDNF protein, related gene expression and activation of the TrkB receptor, along with changes in conditioned-avoidance behavior. BDNF and TrkB are studied as part of neuronal signaling and plasticity. [1]
The result supports further investigation of that pathway in the experimental model. It does not show that raising a BDNF measurement is always beneficial, that the same change occurs throughout the human brain or that a research product improves memory in daily life.
The distinction between a marker and an outcome is useful here. Measuring a signaling protein can help explain a hypothesis, while a behavioral task asks a different question. Neither measurement alone establishes a broad clinical benefit across ages, health conditions and settings.
EXPLORATORY HUMAN BRAIN IMAGING
Panikratova and colleagues reported a 2020 study of 52 healthy participants assigned to separate Semax, Selank or placebo groups. Short-term resting-state MRI measurements identified changes in functional connectivity involving the right amygdala and temporal regions. [2]
Functional connectivity describes relationships between recorded activity patterns. A change in those relationships does not automatically mean better memory, less anxiety or healthier brain function. The study was small and its observation period was brief; it was not a long-term clinical efficacy or safety trial.
It also did not evaluate a Semax/Selank blend. The distinction matters because evidence from separate groups cannot establish the effects of combining the compounds. Imaging observations are informative, but they should remain described as imaging observations.
A STROKE-REHABILITATION REPORT
Gusev and colleagues published a study of 110 people after ischemic stroke in 2018. Participants were grouped by rehabilitation timing, with subgroups receiving or not receiving Semax. The investigators measured plasma BDNF, motor performance and the Barthel index, a measure of independence in daily activities. [3]
The authors reported higher BDNF levels and improved recovery measures associated with Semax, while rehabilitation timing also influenced outcomes. This is relevant clinical research, but the English abstract does not establish that allocation was randomized or that assessment was blinded. It should not be described as a large, definitive placebo-controlled trial. [3]
Plasma BDNF is a blood measurement, not a direct measurement inside the brain. A correlation between a marker and recovery also does not by itself prove that changing the marker caused the recovery. Stroke severity, rehabilitation and other group differences need consideration when interpreting the findings.
WHY THE STUDIES DO NOT ANSWER THE SAME QUESTION
The rat experiment investigates molecular and behavioral responses. The imaging study investigates short-term brain-activity relationships. The rehabilitation report investigates clinical recovery in people who already experienced a stroke. Combining all three into a claim of proven enhancement in healthy adults would cross several unsupported steps.
A stronger evidence base would need well-described controls, adequate participant numbers, meaningful functional endpoints, independent replication and suitable safety follow-up. Those features allow readers to judge not only whether a result was observed but how confidently it can be generalized.
HOW TO INTERPRET THE RESEARCH
Semax has a published research history, but publication alone does not remove study limitations. Terms such as neuroprotection and nootropic should be read in the context of the model, measurement and design rather than treated as guarantees about a product.
The cited reports do not establish comprehensive long-term safety or verify the identity and quality of a separate laboratory batch. They also do not support replacing established stroke care or using research materials personally. This article presents an educational account of the evidence while keeping qualified laboratory research separate from clinical use.
REFERENCES
1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117:54–60.
https://doi.org/10.1016/j.brainres.2006.07.108
2. Panikratova YaR, Lebedeva IS, Sokolov OYu, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. 2020;490:9–11.
https://doi.org/10.1134/S001249662001007X
3. Gusev EI, Martynov MYu, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(3, issue 2):61–68. Russian-language article; English abstract indexed.
https://doi.org/10.17116/jnevro20181183261-68